



#10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Lyon et al. Attny Dkt: 003/240/SAP
U.S. application serial no.: 10/057,532
Filed: January 25, 2002
Title: Recombinant *P. falciparum* Merozoite Protein-1₄₂ Vaccine

* * * * *

24 September 2002

RESPONSE

Commissioner of Patents and Trademarks
Box Sequence Listing
Washington, D.C. 20231

Sir:

This is in response to the Notice to Comply with Sequence Listing Requirements dated July 24, 2002 in the subject application. Herewith submitted is a substitute paper and computer readable form (CRF) copy of the "Sequence Listing" in the subject application.

Kindly replace the previously filed sequence listing with the herein enclosed substitute sequence listing pages 1-14. I hereby state that the content of the substitute paper and computer readable copies are the same and do not include new matter.

Entry of the corrected Sequence Listing is respectfully requested.

Respectfully submitted,

U.S. A. MRCM
504 Scott Street
Fort Detrick, MD 21702-5012
ATTN: MCMR -JA (Elizabeth Arwine-Patent Atty)

By Elizabeth Arwine, Reg. No. 39,441
[Signature] Elizabeth Arwine
U.S. Reg. No. 45,867

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner of Patents and Trademarks, Box Sequence Listing, Box 2327, Arlington, VA 22202, on 24 September 2002.

By Sana A. Pratt
Sana A. Pratt
U.S. Reg. No. 39,441

BEST AVAILABLE COPY



0360

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
TRANSMITTAL FORM

In re Application of Lyon et al. Attny Dkt: 003/240/SAP
U.S. application serial no.: 10/057,532
Filed: January 25, 2002
Title: Recombinant *P. falciparum* Merozoite Protein-1₄₂, Vaccine

Title: Recombinant *P. falciparum* Merozoite Protein-1₄₂ Vaccine

* *

24 September 2002

Honorable Commissioner of
Patents and Trademarks
Washington, D. C. 20231

Sir:

Transmitted for filing herewith are the following items:

Fee required \$-0-

Please charge the above fee and any missing or inadequate fee re this paper to Deposit Account No. **21-0380** for which purpose a duplicate copy of this sheet is attached.

Respectfully submitted,

by Elizabeth Arwine, Reg No 39,441
Elizabeth Arwine
U.S. Agent No. 45,867

U.S. Army Medical and Materiel Command
504 Scott Street
Fort Detrick, Maryland 21702-5012
ATTN: MCMR JA (Ms. Elizabeth Arwine- Patent Atty)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Honorable Commissioner of Patents and Trademarks, Box Sequence, P.O.Box 2327 Arlington, VA 22202, on the date of September 24, 2002.

Respectfully submitted,

by Sara A. Pratt

BEST AVAILABLE COPY



O I P F
JCTOS
SEP 26 2002
UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/057,532	01/25/2002	Jeffrey A. Lyon	003/240/SAP

ATTN: MCMR-JA (Ms. Elizabeth Arwine-PATENT ATTY)
U. S. Army Medical Research and Materiel Command
504 Scott Street
Fort Detrick, MD 21702-5012

CONFIRMATION NO. 2344
FORMALITIES LETTER



OC00000008503083

Date Mailed: 07/24/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

[Signature]
J. Lyon
A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

BEST AVAILABLE COPY